Overdose deaths and synthetic opioids

The CDC NCHS overdose dataset and what it shows

The CDC National Center for Health Statistics (NCHS) publishes provisional drug-overdose death data on a rolling basis, updated monthly with a lag for cause-of-death adjudication. The dataset breaks deaths out by the substance categories that appear on the death certificate, including natural and semi-synthetic opioids (the prescription-opioid category), methadone, heroin, synthetic opioids other than methadone (the category that captures illicit fentanyl and analogues), cocaine, and psychostimulants with abuse potential (largely methamphetamine).

Two qualitative trends in that dataset have driven the policy and clinical conversation. First, the synthetic-opioid category — dominated by illicitly manufactured fentanyl rather than legitimate pharmaceutical fentanyl — has grown from a contributor to a clear plurality of overdose deaths over the past decade. Second, the share of overdose deaths involving more than one substance has risen sharply, with fentanyl increasingly co-detected alongside stimulants, the veterinary sedative xylazine, benzodiazepines, and other depressants.

Program administrators should reference the CDC NCHS provisional overdose page directly rather than memorizing specific counts, because the data are revised on a continuous basis and any single quarterly number is superseded as more death certificates are coded. The structural trend, however, has been stable enough to drive testing-panel design decisions across workplace, clinical, and harm-reduction settings.

How synthetic opioids took over the category

The first wave of the modern U.S. opioid crisis, beginning in the late 1990s, was driven by prescription-opioid mortality. The second wave, after roughly 2010, was driven by heroin as supply chains shifted and prescription access tightened. The third wave — beginning in 2013 and accelerating through 2015 and 2016 — has been driven by illicitly manufactured fentanyl and its analogues entering the U.S. drug supply, initially mixed into heroin and counterfeit prescription pills, and now increasingly as the dominant adulterant in stimulant supplies as well.

Illicit fentanyl reaches the U.S. supply primarily as finished product or precursor chemicals routed through international supply chains. The combination of high potency per unit weight, low cost relative to plant-based opioids, and ease of pressing into counterfeit pills that visually resemble prescription oxycodone, alprazolam, or methamphetamine has made fentanyl the dominant clandestine opioid in the U.S. market. NIDA and CDC have repeatedly described the resulting pharmacology as a step-change in overdose risk because of the narrow margin between an active and a lethal dose for an opioid-naive user.

Fentanyl analogues — including carfentanil, acetylfentanyl, and a long tail of structural variants — appear and disappear in the supply on a faster cycle than legacy controlled-substance scheduling can track. DEA emergency-scheduling actions and class-wide scheduling efforts have attempted to keep pace, with mixed results. The net operational reality for program buyers is that any program testing for opioid exposure in a population at risk for illicit-supply contact needs to assume fentanyl is present rather than treating it as an edge case.

The polysubstance era

The single largest shift in the CDC NCHS dataset over the past several years has been the rise of polysubstance overdose. Decedent toxicology increasingly identifies multiple contributing substances — fentanyl plus methamphetamine, fentanyl plus cocaine, fentanyl plus benzodiazepines, fentanyl plus the veterinary sedative xylazine, and combinations involving novel benzimidazole opioids. The clinical and harm-reduction literature now refers to this as the fourth wave of the overdose crisis.

Fentanyl-stimulant co-involvement is the most numerically significant polysubstance pattern. Stimulant-positive decedents now commonly test positive for fentanyl, often without the decedent\u0027s knowledge that the stimulant supply was contaminated. The clinical implication is that any patient or employee with documented stimulant exposure should be assessed for incidental fentanyl exposure, and harm-reduction programs serving stimulant users have shifted to distributing fentanyl test strips as a default rather than an opioid-population-only intervention.

Xylazine — an alpha-2 adrenergic agonist used as a veterinary sedative and not currently a controlled substance in many jurisdictions — has entered the illicit opioid supply across multiple U.S. regions and complicates clinical management because naloxone reverses the opioid component but not the xylazine sedation. The White House Office of National Drug Control Policy designated xylazine-fentanyl combinations as an emerging threat, and CDC and FDA have published clinical advisories on recognition and management. Xylazine-specific testing, historically a veterinary or research analyte, is moving into clinical and harm-reduction workflows.

Novel synthetic opioids — benzimidazoles and other classes

Beyond fentanyl and its analogues, a separate class of novel synthetic opioids — the benzimidazoles, often referred to in the literature as nitazenes — has appeared in the U.S. supply with growing frequency. Compounds such as isotonitazene and etonitazene have been identified in decedent toxicology, drug-checking programs, and law-enforcement seizures. The DEA has emergency-scheduled several of these compounds into Schedule I as they have been characterized, but the pattern of new-analogue emergence has continued.

The structural variety of novel synthetic opioids matters for testing because immunoassay devices designed against fentanyl do not necessarily cross-react with benzimidazoles, and benzimidazole-specific assays remain primarily a laboratory rather than point-of-care option as of this writing. Programs serving populations with significant illicit-supply contact — addiction treatment, harm reduction, county jails and reentry programs — should plan for confirmatory toxicology by LC-MS/MS that includes a novel-opioid panel rather than relying exclusively on point-of-care screening.

The table below summarizes the major classes of novel and illicit synthetic opioids currently most relevant to U.S. testing programs. The list is illustrative rather than exhaustive; the DEA Diversion Control Division emerging-threat updates and NIDA research-topic pages should be consulted for current additions.

Harm-reduction infrastructure and why it matters to testing programs

The federal harm-reduction infrastructure has expanded substantially since 2021, with SAMHSA grant programs, CDC overdose-prevention funding, and state-level investment in syringe-services programs, naloxone distribution, and drug-checking services. The harm-reduction field has driven adoption of fentanyl test strips as a standard intervention, has piloted xylazine test strips, and has built the laboratory drug-checking networks that surface emerging-threat data faster than decedent-toxicology pipelines can.

For employer and clinical testing programs, harm-reduction data are a leading indicator. The compounds that drug-checking programs identify in a regional supply this quarter are typically the compounds that will appear in workplace and clinical testing the following year, as that supply contaminates a wider population. Program administrators in regions with active drug-checking networks should monitor the published findings as part of their panel-design refresh cycle.

The SAMHSA Overdose Prevention page, the CDC Drug Overdose page, and the NIDA Research Topics pages on fentanyl and novel synthetic opioids are the most useful public-facing references for keeping a program current. These are also the most appropriate sources to cite in policy documentation, supervisor training materials, and donor-facing fact sheets.

Testing-program implications

The most immediate implication of the synthetic-opioid era for testing programs is that an opiate immunoassay alone — the SAMHSA-5 opiate analyte targeting morphine, codeine, and 6-acetylmorphine — does not detect fentanyl, does not detect benzimidazoles, does not detect tramadol, and provides only limited cross-reactivity to oxycodone and methadone. A program that uses only an opiate analyte to screen an opioid-exposed population will systematically miss the substances most likely to be present.

The minimum modern configuration for programs serving populations at risk for illicit-supply exposure adds fentanyl as a dedicated analyte (FYL or FTY on most cassettes), oxycodone (OXY), methadone (MTD), buprenorphine (BUP), and tramadol (TRA) alongside the legacy OPI screen. Programs serving harm-reduction or treatment populations should also plan for LC-MS/MS confirmation with a panel that includes fentanyl analogues, benzimidazoles, and xylazine as needed.

Fentanyl test strips — historically a harm-reduction tool — have moved into clinical workflows as a low-cost adjunct to immunoassay screening, useful when a rapid yes/no on fentanyl exposure is needed and a full immunoassay or LC-MS/MS turnaround is impractical. Xylazine test strips are an emerging analog, with growing institutional adoption among methadone clinics, syringe-services programs, and reentry-medical providers in regions with documented xylazine contamination.

Program-design takeaways for the synthetic-opioid era

The synthetic-opioid era has shifted three foundational assumptions that older drug-testing programs were built around. The first assumption — that opiate-class immunoassay covers the practical universe of opioid exposure — is no longer accurate, because the substances driving overdose mortality are now outside that assay's detection scope. The second assumption — that single-substance overdose is the dominant pattern — has been replaced by a polysubstance reality that calls for broader screening, lower thresholds for laboratory escalation, and tighter coordination between toxicology and clinical care. The third assumption — that the U.S. illicit supply changes slowly enough that a once-a-decade panel refresh is sufficient — has been replaced by a supply that introduces new structural classes on a yearly cadence.

Programs that have adapted well to those shifts share a few common features. They maintain a written panel-design rationale rather than treating panel composition as a vendor recommendation. They review the rationale annually against CDC, NIDA, and SAMHSA emerging-threat communications and regional drug-checking data. They escalate to LC-MS/MS more readily than they once did, recognizing that screening alone cannot distinguish a fentanyl positive from a benzimidazole positive. And they document the basis for adding or omitting any analyte so that a defensible record exists if the panel composition is ever challenged.

Programs that have struggled tend to share the opposite pattern — a panel inherited from a prior administrator with no documentation of the underlying decisions, an opiate-only opioid screen, no fentanyl-specific analyte, no relationship with a confirmation laboratory that maintains an emerging-threat panel, and no scheduled refresh cadence. For program buyers evaluating their own program against current best practice, those gaps are the most actionable place to start.

Finally, the population the program serves matters as much as the regional supply. A safety-sensitive workplace screening a stable employee population in a low-prevalence region faces a different operational landscape than a methadone clinic, a county jail intake unit, or a syringe-services program in a region with active fentanyl-xylazine contamination. The right panel is the one calibrated to the population, the supply, the regulatory framework, and the program's adverse-action workflow — not a single one-size answer derived from a national average.